Spotlight On High Doses Again After Pfizer Duchenne Gene Therapy Death
US Regulator May Call For Limits
The death in Pfizer’s Phase I study could reflect wider safety issues for AAV-based gene therapy and could spur intervention from regulators in 2022.
